New data show that an acetylcholine-preserving drug may halt or lessen cognitive, functional, and behavioral symptoms associated with Alzheimer disease.
In a multicenter study of 353 patients with mild to moderate Alzheimer disease, those treated with 24 mg/d of galantamine maintained or improved their scores on the Alzheimer's Disease Assessment Scale during a 1-year period. The scale measures memory, language, orientation, and other aspects of cognition. Patients in the study also maintained activities of daily functioning for a year. The data were presented last month at the Stockholm/Springfield Symposium in Sweden.
Voelker R. Promising Alzheimer Drug. JAMA. 2000;283(18):2379. doi:10.1001/jama.283.18.2379-JWM00003-3-1
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: